Crescent Bio Q3 net loss $24.6M; cash $133.3M; CR-001 IND on track

CRESCENT BIOPHARMA, INC.

Net loss of $24.6M ($1.27 per share) for Q3 2025; R&D expense $20.3M, G&A $5.5M.
Cash position $133.3M as of Sept 30, 2025, expected to fund operations through 2027.
IND submission for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; Phase 1 start Q1 2026.
Preclinical data for CR-001 presented at SITC showing cooperative pharmacology and anti-tumor activity.
ADC program CR-002 IND submission expected mid-2026; CR-003 also advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.